Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
Cells · 22.02.2023 · 12 (5) · 687
DOI: 10.3390/cells12050687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 22.02.2023. Verfasst von Fumimasa Tomooka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer, has high mortality rates because of its limited treatment options and acquired resistance to chemotherapy. Sulforaphane (SFN), a naturally occurring organosulfur compound found in cruciferous vegetables, exhibits multiple therapeutic properties, such as histone deacetylase (HDAC) inhibition and anti-cancer effects. This study assessed the effects of the combination of SFN and gemcitabine (GEM) on human iCCA cell growth. HuCCT-1 and HuH28 cells, representing moderately differentiated and undifferentiated iCCA, respectively, were treated with SFN and/or GEM. SFN concentration dependently reduced total HDAC activity and promoted total histone H3 acetylation in both iCCA cell lines. SFN synergistically augmented the GEM-mediated attenuation of cell viability and proliferation by inducing G2/M cell cycle arrest and apoptosis in both cell lines, as indicated by the cleavage of caspase-3. SFN also inhibited cancer cell invasion and decreased the expression of pro-angiogenic markers (VEGFA, VEGFR2, HIF-1α, and eNOS) in both iCCA cell lines. Notably, SFN effectively inhibited the GEM-mediated induction of epithelial–mesenchymal transition (EMT). A xenograft assay demonstrated that SFN and GEM substantially attenuated human iCCA cell-derived tumor growth with decreased Ki67+ proliferative cells and increased TUNEL+ apoptotic cells. The anti-cancer effects of every single agent were markedly augmented by concomitant use. Consistent with the results of in vitro cell cycle analysis, G2/M arrest was indicated by increased p21 and p-Chk2 expression and decreased p-Cdc25C expression in the tumors of SFN- and GEM-treated mice. Moreover, treatment with SFN inhibited CD34-positive neovascularization with decreased VEGF expression and GEM-induced EMT in iCCA-derived xenografted tumors. In conclusion, these results suggest that combination therapy with SFN with GEM is a potential novel option for iCCA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
ORCID-Profile: Norihisa Nishimura, Satoshi Iwai, Koh Kitagawa, Tadashi Namisaki, Takemi Akahane
Zitieren
APA
Tomooka, F., Kaji, K., Nishimura, N., Kubo, T., Iwai, S., Shibamoto, A., Suzuki, J., Kitagawa, K., Namisaki, T., Akahane, T., Mitoro, A., & Yoshiji, H. (2023). Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity. Cells, 12(5), 687. https://doi.org/10.3390/cells12050687
Vancouver
Tomooka F, Kaji K, Nishimura N, Kubo T, Iwai S, Shibamoto A, et al. Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity. Cells. 2023;12(5):687. doi:10.3390/cells12050687
BibTeX
@article{Tomooka2023,
author = {Tomooka, Fumimasa and Kaji, Kosuke and Nishimura, Norihisa and Kubo, Takahiro and Iwai, Satoshi and Shibamoto, Akihiko and Suzuki, Junya and Kitagawa, Koh and Namisaki, Tadashi and Akahane, Takemi and Mitoro, Akira and Yoshiji, Hitoshi},
title = {Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity},
journal = {Cells},
year = {2023},
volume = {12},
number = {5},
pages = {687},
doi = {10.3390/cells12050687}
}
EUVIMED